Intranasal Drug Delivery - US Market Trends & Analysis

1.METHODOLOGY
Study Reliability and Reporting Limitations
Disclaimers
Quantitative Techniques & Reporting Level
2.GLOBAL MARKET OVERVIEW AND OUTLOOK
Drug Delivery: A Quick Primer
The Nose: An Attractive Avenue to Cross the Blood Brain Barrier
Self-Administration of Drugs Brings Intranasal Drug Delivery Into the Spotlight
Research & Technology Opens Up New Therapeutic Areas for Nasal Drug Delivery
Recent Product Developments in the US Intranasal Drug Delivery Market (2007)
R&D: Critical to the Commercialization of Intranasal Drug Delivery
Tight Junction Biology: A Key Speed Breaker in Commercialization
RNA Interference (RNAi): A Tool To Manipulate Tight Junctions
Why Is Nasal Drug Delivery the Theme of All Drug Delivery Research Projects?
Nasal Drug Delivery Devices & Equipments Preservative Free Systems (P.F.S.)
Traditional Vs Advanced Intranasal Drug Delivery Devices
Pitfalls Of Traditional Delivery Devices
The Promise of New Advanced Delivery Devices
Bi-Directional Nasal Drug Delivery: A Technology With a Huge Potential
Benefits of Bi-Directional Delivery Authenticated Through Research Studies
Market for Nasal Spray Devices in the US
GSK Wields the Leadership Scepter in the US Intranasal Drugs Market
The Batting Order
3.MARKET DYNAMICS
Innovation in Drug Delivery: A Talisman for Success
Controlled Release Technology is the Buzz Word
Target-Specific Delivery Devices: Of Critical Value
Safety & Cost: Primary Growth Drivers
Preservatives Losing Sheen in Nasal Spray Formulations
Multi-Dose Containers Evolve to Offer Resistance Against Microbial Contamination
Bioavailability: An Important Facet of Intranasal Drug Delivery
Chemical Modification
Transient Modification & Limited Enzymatic Activity
Bioavailability of Large Molecules
Bio-Adhesive Polymers: Useful in Increasing Drug Absorption
Mixed Opinions on Efficiency of Calcitonin Nasal Spray
Nasal Preparations Gaining Foothold in Cough and Allergic Categories
Patent Expiries Impact Market Opportunities
4.PRODUCT FACTS
5.RECENT TECHNOLOGICAL DEVELOPMENTS
New-Generation Technologies and Devices
ViaNase from Kurve Technology
A New Product from OptiNose
Nastech’s "Tight Junction Biology" Research Program
ChiSys™ Nasal Delivery Technology from Archimedes
6.CORPORATE DEVELOPMENTS
Zelos Therapeutics Collaborates with Aegis Therapeutics
ImmuneRegen BioSciences Partners with LRRI
Avamys™ Nasal Spray Receives Approval in Europe
PMI-150 Receives Canadian Patent
Nastech Enrolls 551 Patients for Phase 2 Trials of PYY3-36 Nasal Spray
USFDA Approves FluMist® for Young Children
USFDA Approves Veramyst Nasal Spray for Individuals Aged Two Years and Above
Kurve Technology Inks Agreement with Schering-Plough
MedImmune Clarifies FDA Observations
FluMist(R) Receives FDA Approval for Refrigerated Formulation
Nastech Regains Rights for PTH1-34 Nasal Spray
NASONEX(R) Receives Ease-of-Use Commendation from Arthritis Foundation
Aegis Therapeutics Establishes Cedar Therapeutics Inc.
EMEA Provides Encouraging Feedback for Avamys™ Nasal Spray
Kurve Technologies Introduces Blog on Nasal Drug Delivery
Archimedes Pharma Commences Phase III Trials for NasalFent®
Archimedes Presents New Clinical Data on NasalFent®
LigoCyte Commences Clinical Trials for Intranasal Norovirus Vaccine
Javelin Pharmaceuticals Reveals Phase 2 Study Results for PMI-100/150
Javelin Pharmaceuticals Commences Phase III Studies for PMI-150
Nastech Commences Phase 2 Trials for Insulin Nasal Spray
ACAAI Reveals Results for Trials of Nasacort® AQ Nasal Spray in Children
7.MAJOR PLAYERS
Aegis Therapeutics LLC (USA)
Alza Corporation (USA)
AptarGroup, Inc. (USA)
Archimedes Pharma Limited. (UK)
AstraZeneca Plc (UK)
MedImmune, Inc. (USA)
Bayer Consumer Care (USA)
Bespak Plc (UK)
GlaxoSmithKline Plc (UK)
Intranasal Therapeutics, Inc. (USA)
Javelin Pharmaceuticals, Inc (USA)
Kurve Technology, Inc. (USA)
MDRNA, Inc. (USA)
Novartis AG (Switzerland)
OptiNose AS (Norway)
Pfizer, Inc. (USA)
Rexam Plc (UK)
Schering-Plough Corporation (USA)
Sanofi-Aventis S.A. (France)
Unigene Laboratories, Inc. (USA)
8.MARKET ANALYTICS
Table 1: The US Nasal Drug Delivery Market: Sales Of Top Six Nasal Formulations for The Year 2005 (In US$ Million)
Table 2: Percentage Market Shares of Leading Intranasal Drug Delivery Players in the US –
Table 3: Percentage Shares of Intranasal Drugs Manufacturer Value in the US –
Table 4: Top 10 Nasal Sprays, Drops and Inhalers Brands Ranked by Dollar Sales Through Drug Stores in the US – 2008 (In US $ Million)
Table 5: Top 10 Nasal Sprays, Drops and Inhalers Brands Ranked by Unit Sales through Drug Stores in the US – 2008 (In Thousand Units)
Table 6: Top Five Nasal Sprays Ranked by Dollar Retail Sales in the US – 2008 (In US $ Million)
Table 7: Projected Revenues for Intranasal Sexual Dysfunction Drugs in the US –2010, 2011 & 2012 (in US$ Million)
Table 8: Intranasal Drug Delivery Market by Therapeutic Area in the US: 2007-2015 (Sales in US$ Million)
Table 9: Percentage Breakdown of Intranasal Drug Delivery Market by Therapeutic Area in the US for the Years 2008 & 2009
Companies Profiled